The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms(2020)
被引量:3
摘要
Pancreatic neuroendocrine neoplasms(pNENs)are highly heterogeneous,and the management of pNENs patients can be intractable.To address this challenge,an expert committee was established on behalf of the Chinese Pancreatic Surgery Association,which consisted of surgical oncologists,gastroenterologists,medical oncologists,endocrinologists,radiologists,pathologists,and nuclear medicine specialists.By reviewing the important issues regarding the diagnosis and treatment of pNENs,the committee concluded evidence-based statements and recommendations in this article,in order to further improve the management of pNENs patients in China.
基金
supported by the Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences(CIFMS)2017-I2M-1-001.
参考文献7
-
1Wenming Wu,Gang Jin,Haimin Li,Yi Miao,Chunyou Wang,Tingbo Liang,Jinrui Ou,Yongfu Zhao,Chunhui Yuan,Yixiong Li,Wenhui Lou,Zheng Wu,Renyi Qin,Huaizhi Wang,Jihui Hao,Xianjun Yu,Heguang Huang,Guang Tan,Xubao Liu,Kesen Xu,Lei Wang,Yinmo Yang,Chunyi Hao,Weilin Wang,Kejian Guo,Junmin Wei,Yifan Wang,Chenghong Peng,Xuefeng Wang,Shouwang Cai,Jianxin Jiang,Xinmin Wu,Xiao Yu,Fei Li,Yupei Zhao,无.The current surgical treatment of pancreatic neuroendocrine neoplasms in China: a national wide cross-sectional study[J].Journal of Pancreatology,2019,2(2):35-42. 被引量:11
-
2Tao Ming,Yuan Chunhui,Xiu Dianrong,Shi Xueying,Tao Liyuan,Ma Zhaolai,Jiang Bin,Zhang Zhipeng,Zhang Lingfu,Wang Hangyan.Analysis of risk factors affecting the prognosis of pancreatic neuroendocrine tumors[J].Chinese Medical Journal,2014(16):2924-2928. 被引量:13
-
3G.d’Assignies,A.Couvelard,S.Bahrami,M.P.Vullierme,P.Hammel,O.Hentic,朱玉兆.胰腺内分泌肿瘤:灌注CT评价的肿瘤血流反映了血管发生并与预后因素相关[J].国际医学放射学杂志,2009,32(2):186-186. 被引量:57
-
4Mahmoud M.Al-Hawary,Isaac R.Francis,Suresh T.Chari,Elliot K.Fishman,David M.Hough,David S.Lu,Michael Macari,Alec J.Megibow,Frank H.Miller,Dushyant V.Sahani,Diane M.Simeone,黄翔,孙灿辉.胰腺导管腺癌放射学报告模板:腹部放射协会和美国胰腺协会的共识声明[J].影像诊断与介入放射学,2014,23(4):350-357. 被引量:57
-
5Chen Luohai,Chen Jie.Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors[J].Journal of Pancreatology,2019,2(3):91-99. 被引量:11
-
6Xu Han,Wenhui Lou.Concomitant pancreatic neuroendocrine tumors in hereditary tumor syndromes: who, when and how to operate?[J].Journal of Pancreatology,2019,2(2):48-53. 被引量:7
-
7Suizhi Gao,Xiaohan Shi,Hongyun Ma,Huan Wang,Bo Li,Bin Song,Shiwei Guo,Gang Jin.The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection[J].Journal of Pancreatology,2020,3(4):167-172. 被引量:12
二级参考文献44
-
1LIU Hong ZHANG Su-zhan WU Yu-lian FANG He-qing LI Jiang-tao SHENG Hong-wei WANG Yong.Diagnosis and surgical treatment of pancreatic endocrine tumors in 36 patients:a single-center report[J].Chinese Medical Journal,2007(17):1487-1490. 被引量:11
-
2Siegel R,Naishadham D, Jemal A. Cancer statistics, 2012. CACancer J Clin, 2012,2:10-29.
-
3Vincent A,Herman J,Schulick R,et al. Pancreatic cancer. Lancet,2011,378:607-620.
-
4Howlader N,Noone AM,Krapcho M,et al. SEER Cancer StatisticsReview, 1975-2010, National Cancer Institute. Bethesda, MD.http://seer.cancer.gov/csr/1975_2010/results_merged/sect_22_pancreas.pdf. Accessed May 17,2013.
-
5Lynn M. Matrisian,Rhonda Aizenberg, Aliison Rosenzweig. Thealarming rise of pancreatic cancer deaths in the United StatesiWhywe need to stem the tide today, http://www.pancan.org/section_research/reports/pd?/incidence_report_2012.pdf. PublishedAugust 2012. Accessed May 17,2013.
-
6Conlon KC,Klimstra DS,Brennan MF. Long-term survival aftercurative r^sectionfor pancreatic ductal adenocarcinoma: clinico-pathologicanalysis of 5-year survivors. Ann Surg, 1996,223:273-279.
-
7Varadhachary GR,Tamm EP,Abbruzzese JL,et al. Borderlineresectable pancreatic cancer: definitions, management, and role ofpreoperative therapy. Ann Surg Oncol, 2006,13:1035-1046.
-
8Bilimoria KY,Talamonti MS, Sener SF,et al. Effect of hospitalvolume on margin status after pancreaticoduodenectomy forcancer. J Am Coll Surg, 2008,7:510-519.
-
9Hernandez J, Mullinax J, Clark W, et al.Survival after pancrea-ticoduodenectomy is not improved by extending resections toachieve negative margins. Ann Surg, 2009,50:76-80.
-
10Tamm EP, Balachandran A, Bhosale PR,et al. Imaging ofpancreatic adenocarcinoma : update on staging/resectability.Radiol Clin North Am, 2012,50:407-428.
共引文献133
-
1田娜,李会龙.唐氏治血四法联合奥曲肽治疗消化性溃疡合并上消化道出血的有效性研究[J].中华中医药学刊,2022,40(3):240-243. 被引量:10
-
2高嘉浩(综述),张家文(审校).胰腺肿瘤影像组学的研究进展[J].临床放射学杂志,2020,39(9):1881-1884. 被引量:4
-
3陈克敏,林晓珠,刘玉.灌注CT在胰头部肿块定性诊断中的应用[J].中国实用外科杂志,2009,29(8):630-633.
-
4李靖,白人驹,孙浩然,汪俊萍.胰岛素瘤的MSCT和MRI特征[J].中国医学影像技术,2009,25(11):2061-2064. 被引量:8
-
5周志平,施鑫.CT灌注成像在肿瘤血管生成中的应用[J].临床肿瘤学杂志,2009,14(12):1140-1143. 被引量:3
-
6施鑫,吴苏稼,靳激扬,周志平.骨肉瘤CT灌注成像与血管生成的关系[J].中国肿瘤临床,2010,37(9):512-516. 被引量:1
-
7柴瑞梅,任克.CT灌注技术在胰腺中的应用[J].国际医学放射学杂志,2010,33(3):224-227. 被引量:4
-
8罗仕华,郑传胜,冯敢生,孙细梅,周国锋,梁惠民,夏向文,方建林.重组人p53腺病毒基因经介入途径治疗兔VX2肝癌的研究[J].中华肝脏病杂志,2010,18(7):502-505. 被引量:1
-
9杨永贵,郭岗.CT灌注成像技术在肺癌放化疗敏感性研究中的应用[J].实用医学影像杂志,2010,11(4):267-269.
-
10李明焕,于金明.CT灌注成像技术预测恶性肿瘤放化疗敏感性的研究进展[J].中华放射肿瘤学杂志,2010,19(5):474-477. 被引量:1
同被引文献10
-
1Suizhi Gao,Xiaohan Shi,Hongyun Ma,Huan Wang,Bo Li,Bin Song,Shiwei Guo,Gang Jin.The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection[J].Journal of Pancreatology,2020,3(4):167-172. 被引量:12
-
2Chen Luohai,Chen Jie.Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors[J].Journal of Pancreatology,2019,2(3):91-99. 被引量:11
-
3Xu Han,Wenhui Lou.Concomitant pancreatic neuroendocrine tumors in hereditary tumor syndromes: who, when and how to operate?[J].Journal of Pancreatology,2019,2(2):48-53. 被引量:7
-
4楼文晖,韩序.胰腺神经内分泌肿瘤诊断与治疗的热点与难点[J].中华消化外科杂志,2017,16(10):983-986. 被引量:6
-
5刘一铭,连帆,周翔飞,陈文川,刘海宽,姚望,范文哲,李家平,陈洁,王于.肝动脉栓塞术联合长效奥曲肽降低中低级别神经内分泌瘤肝转移负荷的疗效及安全性分析[J].中华医学杂志,2019,99(15):1142-1146. 被引量:13
-
6刘海宽,陈文川,刘一铭,姚望,范文哲,李家平,陈洁,王于.肝动脉栓塞术治疗42例低-中级别乏血供型神经内分泌肿瘤肝转移的近期疗效及安全性分析[J].中华介入放射学电子杂志,2020,8(2):130-134. 被引量:7
-
7王于,陈洁.胰腺神经内分泌肿瘤复杂肝转移的介入及药物治疗策略[J].协和医学杂志,2020,11(4):389-394. 被引量:7
-
8中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组,李景南,陈洁,霍力,姜海行,蒋力明,蔺蓉,邵成浩,王玮,王于,薛玲.胃肠胰神经内分泌肿瘤诊治专家共识(2020·广州)[J].中华消化杂志,2021,41(2):76-87. 被引量:69
-
9刘雪梅,庹必光.胃肠神经内分泌肿瘤的内镜诊断与治疗[J].中华胃肠外科杂志,2021,24(10):854-860. 被引量:7
-
10韩序,楼文晖.遗传性肿瘤综合征相关胰腺神经内分泌肿瘤的外科治疗原则与方法[J].中国实用外科杂志,2019,0(9):921-925. 被引量:3
引证文献3
-
1韩序,楼文晖.胰腺神经内分泌肿瘤的外科决策[J].肝胆外科杂志,2021,29(3):168-170. 被引量:2
-
2鲁生念,敖劲,陈华,黎成芳,马志远,庹必光,刘雪梅.全身多发转移的胰腺血管活性肠肽瘤[J].中华消化杂志,2022,42(2):127-131.
-
3Ming Lu,Panpan Zhang,Jianwei Zhang,Jie Li.Advances in the treatment of gastroenteropancreatic neuroendocrine neoplasms with somatostatin analogues[J].Journal of Pancreatology,2022,5(3):1-14.
二级引证文献2
-
1李婧,王琳,康强,李越华,朱红,陈怡璇,雷学芬.无功能性胰腺神经内分泌肿瘤的临床诊治分析[J].昆明医科大学学报,2023,44(7):47-51. 被引量:1
-
2刘芸廷,李钶.胰岛素瘤相关研究进展[J].临床医学进展,2023,13(5):7378-7385. 被引量:1
-
1吴文铭,陈洁,白春梅,依荷芭丽·迟,杜奕奇,冯仕庭,霍力,姜玉新,李景南,楼文晖,罗杰,邵成浩,沈琳,王峰,王理伟,王鸥,王于,吴焕文,邢小平,徐建明,薛华丹,薛玲,杨扬,虞先濬,原春辉,赵宏,朱雄增,赵玉沛,中华医学会外科学分会胰腺外科学组.中国胰腺神经内分泌肿瘤诊疗指南(2020)[J].中国实用外科杂志,2021,41(6):601-617. 被引量:19
-
2Yanshuo Cao,Yutong Ma,Jiangyuan Yu,Yu Sun,Tingting Sun,Yang Shao,Jie Li,Lin Shen,Ming Lu.Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden[J].Cancer Communications,2020,40(12):746-751. 被引量:1
-
3Abdel-Baset Bani Yaseen,Yasmin Md Radzi,Hussain M. Almohiy,Akshay Kohli,Mohammad Rawashdeh.Strategies to Improve CT Dose Optimization for Hybrid PET/CT Imaging[J].Open Journal of Medical Imaging,2021,11(2):48-57.
-
4席笑迎,杨敏福.2019年心血管核医学研究荟萃[J].中华心血管病杂志(网络版),2020(1):1-7.
-
5Andras Szasz.Therapeutic Basis of Electromagnetic Resonances and Signal-Modulation[J].Open Journal of Biophysics,2021,11(3):314-350. 被引量:1
-
6Eric Kaly,Oumar Sarr,Sékouna Diatta,Abdoul Aziz Diouf,Djibril Diouck,Daouda Ngom.Characterization and Risk Assessment of the Collapse of the Woody Stand of Ecosystems of the Fathala Forest (Saloum Delta Biosphere Reserve-Senegal)[J].American Journal of Plant Sciences,2021,12(7):975-993.